PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8(+) T-cell activity

PI3K inhibitors with differential selectivity to distinct PI3K isoforms have been tested extensively in clinical trials, largely to target tumor epithelial cells. PI3K signaling also regulates the immune system and inhibition of PI3Kδ modulate the tumor immune microenvironment of pre-clinical mouse...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Immunother Cancer
Hlavní autoři: Carnevalli, Larissa S., Sinclair, Charles, Taylor, Molly A., Gutierrez, Pablo Morentin, Langdon, Sophie, Coenen-Stass, Anna M. L., Mooney, Lorraine, Hughes, Adina, Jarvis, Laura, Staniszewska, Anna, Crafter, Claire, Sidders, Ben, Hardaker, Elizabeth, Hudson, Kevin, Barry, Simon T.
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2018
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6307194/
https://ncbi.nlm.nih.gov/pubmed/30587236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0457-0
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky